Who Supplies Axitinib to India from BRAZIL

To import finished pharmaceutical formulations containing Axitinib into India, the foreign manufacturer must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This process involves submitting an application along with necessary documents, including a Free Sale Certificate, Good Manufacturing Practice (GMP) certificate, and a Certificate of Pharmaceutical Product (CoPP). The registration is valid for three years from the date of issue. Additionally, the importer must possess a valid Import License issued by CDSCO under Form 10 of the Drugs and Cosmetics Rules, 1945. The application for the Import License requires submission of Form 41, which is granted after evaluating the safety, efficacy, and quality data of the product. The timeline for obtaining these registrations can vary but typically ranges from several weeks to a few months, depending on the completeness of the application and the regulatory workload. For formulations under HS Code 30049049, specific requirements include detailed product information, manufacturing process details, and stability data.

Imported finished pharmaceutical formulations containing Axitinib must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors perform port inspections, which may include sampling for quality testing. The batch-wise testing ensures that each shipment meets the required quality standards before distribution in the Indian market.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical products, including mandatory import registration and licensing for all imported drugs. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. Bilateral agreements between India and Brazil have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined import procedures.

India imports finished Axitinib formulations primarily due to the presence of patented or branded products not manufactured domestically. Specific dosage forms, such as extended-release tablets or combination therapies, may not be available from local manufacturers. While India has a robust pharmaceutical manufacturing sector, certain specialized formulations require importation to meet patient needs. The market size for Axitinib formulations in India is growing, driven by increasing cancer incidence and the need for targeted therapies.

The Basic Customs Duty (BCD) on finished pharmaceutical formulations under HS Code 30049049 is 10%. A Social Welfare Surcharge (SWS) of 10% is levied on the BCD, resulting in an effective duty rate of 11%. Integrated Goods and Services Tax (IGST) is applicable as per prevailing rates, which vary based on the product classification and other factors. There are no specific exemptions or concessional duties for imports from Brazil under this HS code.

India sources finished Axitinib formulations from Brazil due to the presence of patented formulations and specialized dosage forms not available from other suppliers. Brazil's pharmaceutical industry adheres to international quality standards, ensuring the reliability of the products. While other countries like China, Germany, and the United States also supply Axitinib formulations, Brazil's competitive advantage lies in its unique product offerings and established trade relations with India. Brazil's share in India's Axitinib import market is significant, reflecting its strong position as a supplier.

India imports finished Axitinib formulations from Brazil due to the availability of patented formulations and specialized dosage forms not produced domestically. Brazil's adherence to international quality standards and established trade relations with India further enhance its attractiveness as a supplier.

Compared to other origins like China, the European Union, and the United States, Brazil offers competitive pricing and quality for Axitinib formulations. Brazil's unique advantage lies in its specialized product offerings and the ability to meet specific regulatory requirements, making it a preferred source for certain formulations.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. While Brazil has a stable trade relationship with India, importers should remain vigilant and have contingency plans in place to mitigate these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure cost-effectiveness.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers to ensure compliance with regulatory standards and quality expectations.

1. 1Directorate General of Foreign Trade (DGFT) Importer Exporter Code (IEC): Obtain an IEC for customs clearance.
2. 2CDSCO Form 40/41: Register the product and obtain an Import Registration Certificate.
3. 3Drug Import License: Apply for a license under Form 10 of the Drugs and Cosmetics Rules, 1945.
4. 4No Objection Certificate (NOC): If applicable, obtain an NOC from the manufacturer.
5. 5Customs Broker: Engage a licensed